BioTech 365

AUGUST 26, 2021

Rebuttal to 8/25/21 Cassava Sciences Press Release Rebuttal to 8/25/21 Cassava Sciences Press Release WASHINGTON–(BUSINESS WIRE)–On August 18, 2021, Jordan Thomas of Labaton Sucharow filed a Citizen Petition to the FDA on behalf of our clients who collectively have expertise … Continue reading →

52

52

BioTech 365

JANUARY 20, 2022

Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today SANTA MONICA, Calif., 20, 2022 (GLOBE NEWSWIRE) — Correction: Opiant Pharmaceuticals, Inc.

40

40

BioTech 365

FEBRUARY 17, 2021

Akers Biosciences Responds to Erroneous Earnings Call Press Release Akers Biosciences Responds to Erroneous Earnings Call Press Release NEW YORK–(BUSINESS WIRE)–Akers Biosciences, Inc.

40

40

BioTech 365

MAY 19, 2021

IBA Press Release: IBA Business Update – First Quarter 2021 IBA Press Release: IBA Business Update – First Quarter 2021 Louvain-La-Neuve, Belgium, 20 May 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions … Continue reading →

40

40

BioTech 365

APRIL 21, 2021

Press release Biocartis Group NV: BIOCARTIS Q1 2021 BUSINESS UPDATE Press release Biocartis Group NV: BIOCARTIS Q1 2021 BUSINESS UPDATE PRESS RELEASE: REGULATED INFORMATION22 April 2021, 07:01 CEST BIOCARTIS Q1 2021 BUSINESS UPDATE70% Cartridge Volume Growth in Q1 2021; New Partnership … Continue reading →

Regulation 40

Regulation 40

BioTech 365

MAY 16, 2021

Press release Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting Press release Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting PRESS RELEASE: REGULATED INFORMATION 17 May 2021, 07:00 CEST Invitation to the Extraordinary Shareholders’ Meeting Mechelen, Belgium, 17 May … Continue reading → (..)

Regulation 40

Regulation 40

BioTech 365

SEPTEMBER 6, 2021

Bone Therapeutics SA reacts to the press release issued by Hybrigenics Bone Therapeutics SA reacts to the press release issued by Hybrigenics Gosselies, Belgium, 7 September, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing … Continue reading →

40

40

BioTech 365

AUGUST 16, 2021

Press release Biocartis Group NV: Second Update on Fire Incident at Biocartis Warehouse Press release Biocartis Group NV: Second Update on Fire Incident at Biocartis Warehouse PRESS RELEASE: 17 August 2021, 07:00 CESTREGULATED INFORMATION – INSIDE INFORMATION Second Update on Fire … Continue reading →

40

40

BioTech 365

MARCH 31, 2021

Press release Biocartis Group NV: Biocartis Announces Publication of 2020 Annual Report Press release Biocartis Group NV: Biocartis Announces Publication of 2020 Annual Report PRESS RELEASE: REGULATED INFORMATION 1 April 2021, 07:00 CEST Biocartis Announces Publication of 2020 Annual Report Mechelen, … Continue reading →

Regulation 40

Regulation 40

pharmaphorum

JULY 26, 2021

The post Digital Awards sponsor push – press release for media partners appeared first on. It currently has over 230 companies as members, including pharma and biotech companies on the industry side and PR, Advertising, Medical Communications, Digital and many other kinds of service company on the agency side.

Branding 52

Branding Marketing Development 52

BioTech 365

NOVEMBER 30, 2021

Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA … Continue reading →

40

40

BioTech 365

SEPTEMBER 22, 2021

Press release Biocartis Group NV: Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line Press release Biocartis Group NV: Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line PRESS RELEASE: 23 September 2021, 07:00 CEST Biocartis Announces Restart of its … Continue reading →

Manufacturing 40

Manufacturing 40

BioTech 365

AUGUST 25, 2021

Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2021 HALF-YEAR RESULTS ON 2 SEPTEMBER 2021 Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2021 HALF-YEAR RESULTS ON 2 SEPTEMBER 2021 PRESS RELEASE: REGULATED INFORMATION 26 August 2021, 07:00 CEST BIOCARTIS ANNOUNCES 2021 HALF–YEAR … Continue reading →

Regulation 40

Regulation 40

Pharmaceutical Technology

JANUARY 8, 2024

The layoffs and scaling back of R&D activities will extend Senti Biosciences' cash runway into Q1 2025, according to a press release.

Trials 162

Trials 162

BioTech 365

MAY 18, 2021

Issues Corrective Press Release Regarding First Quarter 2021 Results Pacific Health Care Organization, Inc. Issues Corrective Press Release Regarding First Quarter 2021 Results Newport Beach, May 18, 2021 (GLOBE NEWSWIRE) — Pacific Health Care Organization, … Continue reading →

40

40

BioTech 365

FEBRUARY 3, 2022

Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity … Continue reading →

Branding 40

Branding 40

BioTech 365

JANUARY 31, 2021

Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells Fourth patient, who spent … Continue reading →

40

40

Eye on FDA

AUGUST 18, 2020

During the first half of the year, FDA issued a record number of press releases and nearly two-thirds (64 percent) were about COVID-19. The first release related to the pandemic appeared on February 24 to inform us about what steps the agency would be taking with respect to foreign inspections.

Gene Therapy 61

Gene Therapy Drugs Production Gene 61

BioTech 365

APRIL 19, 2021

Press release Biocartis Group NV: Biocartis Announces US FDA 510(k) submission of its Idylla™ MSI Test Press release Biocartis Group NV: Biocartis Announces US FDA 510(k) submission of its Idylla™ MSI Test PRESS RELEASE: 20 April 2021, 07:00 CEST Biocartis Announces … Continue reading →

40

40

BioTech 365

FEBRUARY 3, 2021

Correction to Press Release: Extendicare Announces Timing of 2020 Fourth Quarter Results and Year End Results and Conference Call Correction to Press Release: Extendicare Announces Timing of 2020 Fourth Quarter Results and Year End Results and Conference Call MARKHAM, Ontario, … Continue reading →

40

40

BioTech 365

OCTOBER 5, 2020

PRESS RELEASE: 6 October 2020, 07:00 CEST Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™ Mechelen, Belgium, 6 October 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: … Continue reading →

Marketing 40

Marketing 40

BioTech 365

MAY 10, 2021

Press release Biocartis Group NV: Biocartis Receives EUR 1.4m Grant to Support Development of New Idylla™ Technology to Unlock Potential in Molecular Surveillance Press release Biocartis Group NV: Biocartis Receives EUR 1.4m

Development 40

Development 40

BioTech 365

NOVEMBER 16, 2021

Press release Biocartis Group NV: New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer Press release Biocartis Group NV: New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens … Continue reading →

40

40

BioTech 365

APRIL 21, 2021

Press release Biocartis Group NV: Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ Press release Biocartis Group NV: Biocartis and SkylineDx Sign Collaboration to Develop the Merlin … Continue reading →

Development 40

Development 40

Scienmag

JUNE 10, 2021

Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), and Journal of General Physiology (JGP) announce an editorial policy allowing swift and confidential updates to author names at any time and for any reason including changes to gender identity, marriage, divorce, religion, or other personal circumstances.

Medicine 75

Medicine 75

World of DTC Marketing

NOVEMBER 27, 2020

SUMMARY: Business by press release has made pharma executives a lot of money but we still haven’t seen any over reviewed data on COVID 19 vaccines. The results of trials were announced in press releases rather than peer-reviewed papers. Science by press release.

Vaccination 208

Vaccination Vaccine Pharma Companies Trials 208

Bio Pharma Dive

OCTOBER 13, 2022

The findings, which were disclosed in a press release without specific data, are the first immune response results in humans for the reformulated shot targeting the BA.4 5 substrains.

Immune Response 164

Immune Response Antibody Trials 164

BioTech 365

MAY 13, 2021

Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021 Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and … Continue reading →

DNA 52

DNA 52

Pharmaceutical Technology

MARCH 28, 2023

OncoVerity plans to optimise the development of cusatuzumab in acute myeloid leukemia (AML) and other cancers, states the March 27 press release. Smith was appointed as OncoVerity’s chief medical officer, alongside Max Colao as the CEO.

Licensing 130

Licensing Licensing Development Antibody 130

BioTech 365

NOVEMBER 22, 2020

million (after correction of a technical error reflected in the press releases of 6 and 15 July 2020) Shareholder structure of Pixium Vision following the … Continue reading → Shareholder structure of Pixium Vision following the capital increase with pre-emptive subscription rights of €7.3

40

40

Pharmaceutical Technology

APRIL 21, 2023

Over 474,500 cases of leukemia were reported across the world in 2020, per the company’s April 20 press release. months in patients on standard chemotherapy, per a June 2022 press release. The type II FLT3 inhibitor could also be used as continuation monotherapy post consolidation in this set of adult patients.

Branding 246

Branding Drugs Medicine Trials 246

STAT News

APRIL 27, 2023

They trumpet the technology in press releases, plaster its use on billboards, and sprinkle AI into speeches touting its ability to detect diseases earlier and make health care faster, better, and cheaper. In public, hospitals rave about artificial intelligence. Read the rest…

Medicine 124

Medicine Research 124

Fierce Pharma

OCTOBER 2, 2023

The deal will see the asset manager furnish Amicus with a $400 million loan that will be used for the refinancing of existing debt, Amicus said in a press release. . | Amicus unveiled a $430 million financing pact with Blackstone Life Sciences and Blackstone Credit.

Life Science 115

Life Science FDA Approval 115

BioTech 365

JANUARY 13, 2022

RELIEF THERAPEUTICS Holding AG / Key word(s): Legal Matter 14-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Comments on NRx … Continue reading →

40

40

Eye on FDA

AUGUST 10, 2023

The number of press releases issued by FDA during the first six months of the year declined to 101 from the 125 issued by June 30 of last year, the lowest number at mid-year since 2017. In 2022, the agency issued 27 releases that involved the subject of COVID, 18 of which were during the first half of the year.

Containment 80

Containment 80

STAT News

DECEMBER 13, 2022

The data, made public in a press release, represent the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots. Continue to STAT+ to read the full story…

Vaccination 144

Vaccination Vaccine Development Drugs 144

BioTech 365

OCTOBER 7, 2020

Hørsholm, Denmark (7 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”)(formerly Oncology Venture A/S) today announced that its shareholders have approved, at the extraordinary general meeting (EGM) held on October 7, 2020, the adoption of the Company’s new … Continue reading → (..)

40

40